Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
15.31
Nov 20 • 3:59 PM ET Dollar change+0.25 Percentage change(1.66%)
Aftermarket Close
15.31
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
1.06B
Enterprise Value
584.17M
Income
-141.09M
Sales
0.00M
Book/sh
6.79
Cash/sh
6.88
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
55
IPO
Jun 30, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
2.25
P/C
2.23
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
16.03
Current Ratio
16.03
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-2.39
EPS next Y
-2.53
EPS next Q
-0.61
EPS this Y
21.41%
EPS next Y
-0.85%
EPS next 5Y
6.10%
EPS past 3/5Y
61.94% 21.92%
Sales past 3/5Y
- -
EPS Y/Y TTM
78.94%
Sales Y/Y TTM
-
EPS Q/Q
34.69%
Sales Q/Q
-
Insider Own
14.30%
Insider Trans
0.00%
Inst Own
106.03%
Inst Trans
7.88%
ROA
-47.36%
ROE
-51.39%
ROIC
-35.76%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
1.40%
SMA50
2.43%
SMA200
-15.93%
Trades
Shs Outstand
67.08M
Shs Float
59.29M
52W High
28.00 -45.32%
52W Low
11.02 38.93%
Volatility
6.84% 6.34%
ATR (14)
0.98
RSI (14)
50.70
Beta
1.58
Rel Volume
1.12
Avg Volume
910.38K
Volume
1,021,425
Perf Week
-5.14%
Perf Month
2.68%
Perf Quarter
-28.22%
Perf Half Y
-31.07%
Perf YTD
-0.78%
Perf Year
33.36%
Perf 3Y
-71.15%
Perf 5Y
-70.66%
Perf 10Y
-
Prev Close
15.06
Price
15.31
Change %
1.66%
Consensus
Strong Buy
Avg. Price Target
$49.22
Implied Upside
+221.5%
Analysts10incl. previous ratings
Rating Distribution8 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jun 15, 2026Initiated
UBS logoUUBS
Buy$45+193.9%
Jan 07, 2026Initiated
HH.C. Wainwright
Buy$25+63.3%
Oct 09, 2025Initiated
BBTIG Research
Buy$28+82.9%
Jul 14, 2025Initiated
JEF logoJJefferies
Buy$16+4.5%
Jun 16, 2025Upgrade
GGuggenheim
Neutral → Buy$14-8.6%
May 07, 2025Initiated
WWedbush
Outperform$17+11.0%
May 05, 2025Initiated
SF logoSStifel
Buy$19+24.1%
May 02, 2025Initiated
TD logoTTD Cowen
Buy$10-34.7%
Jun 18, 2024Downgrade
WFC logoWWells Fargo
Overweight → Equal Weight$35 → $2-86.9%
Jun 18, 2024Downgrade
TD logoTTD Cowen
Buy → Hold
Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.
PresidentMr. Tom Frohlich
D.V.M.Dr. Andrew James King BVMS
Chief Legal Officer & Corporate SecretaryMs. Elizabeth Balta J.D.
Senior Vice President of PeopleMs. Lori Stewart
Senior Vice President of FinanceMr. Jonathan Quick